|
US7625859B1
(en)
*
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
|
US20050287153A1
(en)
*
|
2002-06-28 |
2005-12-29 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
|
EP1240337B1
(en)
*
|
1999-12-24 |
2006-08-23 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
|
US20040001827A1
(en)
*
|
2002-06-28 |
2004-01-01 |
Dennis Mark S. |
Serum albumin binding peptides for tumor targeting
|
|
US20060228364A1
(en)
*
|
1999-12-24 |
2006-10-12 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
|
CA2407556C
(en)
*
|
2000-05-19 |
2011-06-21 |
Genentech, Inc. |
Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
|
|
AU2002355477B2
(en)
*
|
2001-08-03 |
2008-09-25 |
Medical Research Council |
Method of identifying a consensus sequence for intracellular antibodies
|
|
EP2289942B1
(en)
*
|
2002-04-10 |
2013-07-31 |
Genentech, Inc. |
Anti-HER2 antibody variants
|
|
AU2005214382B2
(en)
*
|
2004-02-19 |
2011-08-04 |
Genentech, Inc. |
CDR-repaired antibodies
|
|
DK1771482T3
(da)
|
2004-07-22 |
2014-10-20 |
Genentech Inc |
HER2-antistofsammensætning
|
|
MX2007003907A
(es)
*
|
2004-10-05 |
2007-05-21 |
Genentech Inc |
Agentes terapeuticos con toxicidad reducida.
|
|
CA2583230A1
(en)
*
|
2004-10-05 |
2006-04-20 |
Oregon Health And Science University |
Compositions and methods for treating disease
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
CN102580084B
(zh)
|
2005-01-21 |
2016-11-23 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
|
EP1850874B1
(en)
|
2005-02-23 |
2013-10-16 |
Genentech, Inc. |
Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
|
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
|
|
PE20070207A1
(es)
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
|
CA2631327C
(en)
*
|
2005-12-02 |
2015-10-13 |
Genentech, Inc. |
Her2 binding polypeptides and uses thereof
|
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
|
CL2007002404A1
(es)
|
2006-08-21 |
2008-04-18 |
Hoffmann La Roche |
Uso de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular) para el tratamiento de un paciente que padece una recaida de cancer her2 positivo durante o despues del tratamiento con un anticuerpo anti-her2.
|
|
SI2132573T1
(sl)
|
2007-03-02 |
2014-07-31 |
Genentech, Inc. |
Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
|
|
RS53008B2
(sr)
†
|
2007-04-03 |
2022-12-30 |
Amgen Res Munich Gmbh |
Interspecijski specifičan cd3-epsilon vezujući domen
|
|
MX2009010611A
(es)
*
|
2007-04-03 |
2010-03-26 |
Micromet Ag |
Enlazadores biespecificos, especificos para especies.
|
|
US20090258005A1
(en)
*
|
2007-05-29 |
2009-10-15 |
Trubion Pharmaceuticals Inc. |
Therapeutic compositions and methods
|
|
US20090304590A1
(en)
*
|
2007-05-29 |
2009-12-10 |
Wyeth |
Therapeutic compositions and methods
|
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
PL2171090T3
(pl)
|
2007-06-08 |
2013-09-30 |
Genentech Inc |
Markery ekspresji genów odporności guza na leczenie hamujące HER2
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
WO2010051502A2
(en)
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
|
MY152068A
(en)
|
2009-03-20 |
2014-08-15 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
CN102421448A
(zh)
|
2009-05-29 |
2012-04-18 |
霍夫曼-拉罗奇有限公司 |
Her2信号传导调控剂在表达her2的胃癌患者中
|
|
EP2513148B1
(en)
|
2009-12-16 |
2016-08-31 |
AbbVie Biotherapeutics Inc. |
Anti-her2 antibodies and their uses
|
|
US9556249B2
(en)
|
2010-02-18 |
2017-01-31 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
|
CN102167742B
(zh)
|
2010-02-25 |
2014-05-14 |
上海百迈博制药有限公司 |
一种全人源抗her2单克隆抗体、其制备方法及用途
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
|
US10208129B2
(en)
|
2010-12-06 |
2019-02-19 |
National Research Council Of Canada |
Antibodies selective for cells presenting ErbB2 at high density
|
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
MX2014001766A
(es)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Anticuerpos de neuregulina y sus usos.
|
|
IL301603A
(en)
|
2011-10-14 |
2023-05-01 |
Genentech Inc |
Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
|
|
US9327023B2
(en)
|
2011-10-25 |
2016-05-03 |
The Regents Of The University Of Michigan |
HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
BR112014012979A2
(pt)
|
2011-11-30 |
2020-10-20 |
Genentech, Inc. |
mutações erbb3 em câncer
|
|
US9376715B2
(en)
|
2011-12-09 |
2016-06-28 |
Roche Molecular Systems, Inc |
Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
|
|
CA2861003C
(en)
*
|
2012-01-13 |
2023-03-28 |
Julius-Maximilians-Universitat Wurzburg |
Dual antigen-induced bipartite functional complementation
|
|
US20130259867A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
|
KR101505157B1
(ko)
*
|
2012-05-08 |
2015-03-24 |
주식회사 종근당 |
항―ＥｒｂＢ２ 항체 변이체
|
|
US9777067B2
(en)
|
2012-09-27 |
2017-10-03 |
Massachusetts Institute Of Technology |
HER2- and VEGF-A-binding proteins with enhanced stability
|
|
MX338711B
(es)
|
2012-10-12 |
2016-04-28 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas.
|
|
IL238323B2
(en)
|
2012-10-30 |
2023-11-01 |
Esperance Pharmaceuticals Inc |
Antibody/drug conjugates and methods of use
|
|
KR102291355B1
(ko)
|
2012-11-30 |
2021-08-19 |
에프. 호프만-라 로슈 아게 |
Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
|
|
MX362970B
(es)
|
2013-03-13 |
2019-02-28 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas.
|
|
CA2908380A1
(en)
|
2013-04-09 |
2014-10-16 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
MX368259B
(es)
|
2013-04-16 |
2019-09-25 |
Genentech Inc |
Variantes de pertuzumab y su evaluacion.
|
|
WO2014182970A1
(en)
*
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
IL263466B2
(en)
|
2013-12-17 |
2023-10-01 |
Genentech Inc |
Anti-CD3 antibodies and methods of using them
|
|
EP3083696B1
(en)
|
2013-12-20 |
2018-02-14 |
F.Hoffmann-La Roche Ag |
Bispecific her2 antibodies and methods of use
|
|
ES2809729T3
(es)
|
2014-03-11 |
2021-03-05 |
Molecular Templates Inc |
Proteínas que comprenden regiones efectoras de la subunidad A de la toxina Shiga próximas al extremo amino terminal y regiones de unión de tipo inmunoglobulina de reconocimiento celular capaces de unirse específicamente a HER2/neu/ErbB2
|
|
JP6935195B2
(ja)
|
2014-03-11 |
2021-09-15 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
|
|
SG11201608192SA
(en)
*
|
2014-04-11 |
2016-10-28 |
Medimmune Llc |
Bispecific her2 antibodies
|
|
KR20160141857A
(ko)
|
2014-04-25 |
2016-12-09 |
제넨테크, 인크. |
트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
|
|
EP3193940A1
(en)
|
2014-09-10 |
2017-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
KR101515535B1
(ko)
|
2015-01-28 |
2015-05-06 |
주식회사 종근당 |
항―ＥｒｂＢ２ 항체 변이체
|
|
CN105985435B
(zh)
|
2015-01-30 |
2019-10-15 |
嘉和生物药业有限公司 |
全人源her2抗体的突变抗体及其编码基因和应用
|
|
EP3303373B1
(en)
|
2015-05-30 |
2020-04-08 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
|
WO2016196373A2
(en)
|
2015-05-30 |
2016-12-08 |
Genentech, Inc. |
Methods of treating her2-positive metastatic breast cancer
|
|
TW201717935A
(zh)
|
2015-06-03 |
2017-06-01 |
波士頓生醫公司 |
用於治療癌症的組成物和方法
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
CN107787331B
(zh)
*
|
2015-06-17 |
2022-01-11 |
豪夫迈·罗氏有限公司 |
抗her2抗体和使用方法
|
|
KR20180030085A
(ko)
|
2015-07-26 |
2018-03-21 |
몰레큘러 템플레이츠, 인코퍼레이션. |
시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
EP3368092B9
(en)
|
2015-10-29 |
2020-07-29 |
Novartis AG |
Antibody conjugates comprising toll-like receptor agonist
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
EP3430058A4
(en)
|
2016-03-15 |
2019-10-23 |
Generon (Shanghai) Corporation Ltd. |
MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
|
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
|
EP3525829A1
(en)
|
2016-10-11 |
2019-08-21 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
|
WO2018085513A1
(en)
|
2016-11-04 |
2018-05-11 |
Genentech, Inc. |
Treatment of her2-positive breast cancer
|
|
JP7784795B2
(ja)
|
2016-11-15 |
2025-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
|
|
WO2018102427A1
(en)
|
2016-11-29 |
2018-06-07 |
Boston Biomedical, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
EP3562844A1
(en)
|
2016-12-28 |
2019-11-06 |
Genentech, Inc. |
Treatment of advanced her2 expressing cancer
|
|
TW202508629A
(zh)
|
2017-01-17 |
2025-03-01 |
美商建南德克公司 |
皮下her2抗體調配物
|
|
MX2019008840A
(es)
|
2017-01-25 |
2019-09-09 |
Molecular Templates Inc |
Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
|
|
PT3589661T
(pt)
|
2017-03-02 |
2024-01-29 |
Genentech Inc |
Tratamento com adjuvante de cancro da mama positivo para her2
|
|
JP7473339B2
(ja)
*
|
2017-03-07 |
2024-04-23 |
エフ． ホフマン－ラ ロシュ アーゲー |
代替の抗原特異的抗体変異体を発見するための方法
|
|
WO2018200505A1
(en)
|
2017-04-24 |
2018-11-01 |
Genentech, Inc. |
Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
WO2018213424A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
NZ762376A
(en)
|
2017-09-19 |
2022-08-26 |
Scherrer Inst Paul |
Transglutaminase conjugation method and linker
|
|
IL325995A
(en)
|
2018-02-08 |
2026-03-01 |
Genentech Inc |
Bispecific antigen binding molecules and methods of use
|
|
CN110612117B
(zh)
|
2018-04-17 |
2024-04-12 |
分子模板公司 |
包含去免疫化的志贺毒素a亚基支架的her2靶向分子
|
|
CA3098103A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
EA202190749A1
(ru)
|
2018-09-10 |
2021-07-09 |
Мирати Терапьютикс, Инк. |
Способы комбинированной терапии
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
CN113631580B
(zh)
*
|
2019-02-03 |
2024-07-02 |
上海宝济药业股份有限公司 |
抗her2的双特异性抗体及其应用
|
|
WO2021119505A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
|
JP2023511403A
(ja)
*
|
2020-01-23 |
2023-03-17 |
バイオアトラ インコーポレイテッド |
条件的に活性な抗ｈｅｒ２抗体、抗体断片、それらの免疫コンジュゲート、およびそれらの使用
|
|
US20230072955A1
(en)
*
|
2020-01-23 |
2023-03-09 |
Exuma Biotech Corp |
Chimeric antigen receptors to her2 and methods of use thereof
|
|
TWI867218B
(zh)
*
|
2020-04-30 |
2024-12-21 |
大陸商正大天晴藥業集團股份有限公司 |
靶向her2的抗原結合建構體及用途
|
|
JP2023532122A
(ja)
|
2020-06-29 |
2023-07-26 |
ジェネンテック， インコーポレイテッド |
ペルツズマブにトラスツズマブを加えた固定用量配合剤
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
KR20230096052A
(ko)
|
2020-10-25 |
2023-06-29 |
아라리스 바이오테크 아게 |
항체-링커 접합체를 생성하기 위한 수단 및 방법
|
|
IL303350A
(en)
|
2020-12-04 |
2023-08-01 |
Macrogenics Inc |
Pharmaceutical compositions of a her2/neu antibody and use of the same
|
|
US20240101717A1
(en)
*
|
2021-01-22 |
2024-03-28 |
Bionecure Therapeutics, Inc. |
Anti-her-2/trop-2 constructs and uses thereof
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
EP4337330A1
(en)
|
2021-05-14 |
2024-03-20 |
Genentech, Inc. |
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
EP4426727A2
(en)
|
2021-11-03 |
2024-09-11 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
JP2025523630A
(ja)
|
2022-07-04 |
2025-07-23 |
ブイアイビー ブイゼットダブリュ |
血液－脳脊髄液関門通過抗体
|
|
IL318499A
(en)
|
2022-07-30 |
2025-03-01 |
Pinetree Therapeutics Inc |
Compounds for targeted lysosomal degradation and methods of using them
|
|
CN119894936A
(zh)
*
|
2022-09-20 |
2025-04-25 |
普米斯生物技术(珠海)有限公司 |
抗her2抗体及其用途
|
|
TW202434307A
(zh)
|
2023-01-18 |
2024-09-01 |
大陸商泰勵生物科技（上海）有限公司 |
抗體偶聯藥物及其用途
|
|
AU2024243709A1
(en)
|
2023-04-03 |
2025-11-06 |
Katholieke Universiteit Leuven |
Blood-brain barrier crossing antibodies
|
|
WO2026032417A1
(zh)
*
|
2024-08-08 |
2026-02-12 |
石药集团巨石生物制药有限公司 |
Gspt1降解剂和含有gspt1降解剂的抗体偶联物及其用途
|